SCHEMBL20722892

SCHEMBL20722892

NC(Cc1ccc(Cl)nc1Cl)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.45
PKM P14618 2/20 0.45
HSD17B10 Q99714 2/20 0.45
HIF1A Q16665 2/20 0.45
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 2/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.45
BLM P54132 2/20 0.45
PMP22 Q01453 2/20 0.45
KMT2A Q03164 2/20 0.45
RGS12 O14924 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX15 P16050 1/20 0.45
NFKB1 P19838 1/20 0.45
CASP1 P29466 1/20 0.45
BRCA1 P38398 1/20 0.45
THPO P40225 1/20 0.45
CASP7 P55210 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20722890 1.00 USP2 (0.45) USP2PKMHSD17B10HIF1AKDM4E
SCHEMBL30060129 0.81 PTGS2 (0.41) MEN1MAPTKMT2AALDH1A1L3MBTL1
SCHEMBL28586342 0.81 PTGS2 (0.41) MEN1MAPTKMT2AALDH1A1L3MBTL1
SCHEMBL20732114 0.81 PTGS2 (0.41) MEN1MAPTKMT2AALDH1A1L3MBTL1
SCHEMBL31583179 0.80 MAPT (0.41) KDM4EMAPTPOLBRECQLL3MBTL1
SCHEMBL21685384 0.76 SLC6A4 (0.34)
SCHEMBL30968452 0.76 SLC6A4 (0.34)
SCHEMBL20722390 0.76 SLC6A4 (0.34)
SCHEMBL31583141 0.75 EPHX1 (0.38) MEN1MAPTKMT2AALDH1A1POLB
SCHEMBL5288744 0.75 CYP1A2 (0.50) USP2PKMHSD17B10HIF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112867712-B Carboxamide as ubiquitin-specific protease inhibitor 瓦洛早期发现股份有限公司 2024-07-16 CN disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed
EP-3833661-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Valo Early Discovery, Inc. (US) 2021-06-16 EP disclosed
CN-112867712-A Carboxamides as ubiquitin-specific protease inhibitors 瓦洛早期发现股份有限公司 2021-05-28 CN disclosed
EP-3665169-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS Forma Therapeutics, Inc. (US) 2020-06-17 EP disclosed
WO-2020033707-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2020-02-13 WO disclosed
WO-2019032863-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2019-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 USP2 6/4885PKM 3353/4885HSD17B10 3010/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 USP2 6/4885PKM 3353/4885HSD17B10 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.